Discover mobile digital technology for medicine, Novartis collaborates with Qualcomm

Novartis has issued a bulletin that will work with Qualcomm Ventures to set up a joint investment firm that combines Novartis's expertise in drug development and production and Qualcomm's digital and mobile technology to focus on start-ups with new technologies or new products. Although Novartis is a pharmaceutical company, the scope of the investment is "not limited to drugs".

Dr. David Epstein, Novartis's head of pharmaceuticals, said he was very concerned about providing a team of integrated solutions for doctors and patients, or any technological innovation that could lead to industry trends.

As for Novartis's own role, is the desire to use digital medicine to provide patients with appropriate medicines at the right time, such as medical devices that support telephone functions, mobile applications, wearable equipment, and techniques for accurately delivering appropriate drugs to patients with large data and small data and for more accurate drug economic analysis.

A number of new funds for mobile health care, such as the establishment of three mergers and acquisitions funds in 2014, and pharmaceutical companies in the direction of strategic investment mergers and acquisitions, in which Roche has invested in Cancer data Analysis Team FM, Genentech, a biopharmaceutical firm, injected $60 million into 23andMe to share genomic data from Parkinson's patients in the latter.